| Title |
Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review
|
|---|---|
| Published in |
OncoTargets and therapy, August 2018
|
| DOI | 10.2147/ott.s141053 |
| Pubmed ID | |
| Authors |
Eva M Donato, Miguel Fernández-Zarzoso, Jose Antonio Hueso, Javier de la Rubia |
| Abstract |
Hodgkin lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) account for ~10% and 2%-3% of all cases of lymphoid neoplasms, respectively. Up to 30% of patients with HL are refractory or relapse after first-line therapy, and elderly patients with HL represent a subgroup of patients with suboptimal responses to the currently available treatments. Five-year overall survival for ALCL patients is 50%-80% with conventional chemotherapy. Therefore, new therapeutic approaches are needed for these groups of patients. Brentuximab vedotin is a chimeric IgG1 anti-CD30 antibody-drug conjugate that has all the features that are necessary to make a substantive difference with the standard therapies in patients with HL and ALCL: a novel mechanism of action, single-agent activity, non-cross-resistance, and safety both in the relapsed-refractory and in the front-line setting. This review provides an update of the results of the most relevant clinical trials including brentuximab vedotin for patients with HL and ALCL conducted to date. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 41 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 41 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 5 | 12% |
| Student > Postgraduate | 4 | 10% |
| Other | 3 | 7% |
| Researcher | 3 | 7% |
| Student > Bachelor | 2 | 5% |
| Other | 9 | 22% |
| Unknown | 15 | 37% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 22% |
| Biochemistry, Genetics and Molecular Biology | 7 | 17% |
| Nursing and Health Professions | 2 | 5% |
| Agricultural and Biological Sciences | 2 | 5% |
| Mathematics | 1 | 2% |
| Other | 4 | 10% |
| Unknown | 16 | 39% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 July 2020.
All research outputs
#8,266,724
of 25,385,509 outputs
Outputs from OncoTargets and therapy
#487
of 3,016 outputs
Outputs of similar age
#131,605
of 341,886 outputs
Outputs of similar age from OncoTargets and therapy
#19
of 114 outputs
Altmetric has tracked 25,385,509 research outputs across all sources so far. This one has received more attention than most of these and is in the 66th percentile.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 341,886 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 60% of its contemporaries.
We're also able to compare this research output to 114 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 82% of its contemporaries.